Health care stocks were down late Tuesday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) fell 1.4%.
In corporate news, Travere Therapeutics (TVTX) shares rose 13% after the company said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.
Firefly Neuroscience (AIFF) shares surged 174% after it said it was accepted into Nvidia's (NVDA) Connect program.
Novartis (NVS) agreed to buy biopharmaceutical firm Anthos Therapeutics for up to $3.1 billion as the Swiss pharmaceutical giant expands its cardiovascular portfolio. Novartis shares added 0.8%.
Lipella Pharmaceuticals (LIPO) shares jumped 35% after it reported positive topline results from a phase 2a trial of LP-310, a liposomal-tacrolimus oral rinse for oral lichen planus.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。